These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15273367)

  • 21. Presence of multiple copies of the capsulation b locus in invasive Haemophilus influenzae type b (Hib) strains isolated from children with Hib conjugate vaccine failure.
    Cerquetti M; Cardines R; Ciofi Degli Atti ML; Giufré M; Bella A; Sofia T; Mastrantonio P; Slack M
    J Infect Dis; 2005 Sep; 192(5):819-23. PubMed ID: 16088831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A; Hutagalung Y; Watanaveeradej V; Bock HL; Steinhoffmd M
    J Med Assoc Thai; 2007 Jul; 90(7):1330-6. PubMed ID: 17710973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of conjugate vaccines.
    Mäkelä PH; Käyhty H
    Expert Rev Vaccines; 2002 Oct; 1(3):399-410. PubMed ID: 12901578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate.
    Abdelhameed AS; Adams GG; Morris GA; Almutairi FM; Duvivier P; Conrath K; Harding SE
    Sci Rep; 2016 Feb; 6():22208. PubMed ID: 26915577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study.
    Lee EH; Lewis RF; Makumbi I; Kekitiinwa A; Ediamu TD; Bazibu M; Braka F; Flannery B; Zuber PL; Feikin DR
    Trop Med Int Health; 2008 Apr; 13(4):495-502. PubMed ID: 18312475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.
    Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N
    Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoconjugate vaccines against Haemophilus influenzae type b.
    Fernandez Santana V; Peña Icart L; Beurret M; Costa L; Verez Bencomo V
    Methods Enzymol; 2006; 415():153-63. PubMed ID: 17116473
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency.
    Shrimpton A; Duddridge M; Ziegler-Heitbrock L
    Vaccine; 2006 Apr; 24(17):3574-80. PubMed ID: 16507328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction of Haemophilus influenzae type B conjugate vaccine into routine immunization in Ghana and its impact on bacterial meningitis in children younger than five years.
    Renner LA; Newman MJ; Ahadzie L; Antwi-Agyei KO; Eshetu M
    Pediatr Infect Dis J; 2007 Apr; 26(4):356-8. PubMed ID: 17414404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies.
    Ek T; Mellander L; Hahn-Zoric M; Abrahamsson J
    Acta Paediatr; 2006 Jun; 95(6):701-6. PubMed ID: 16754551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural and vaccine-induced immunity against Haemophilus influenzae type b in patients with beta-thalassemia.
    Spoulou VI; Tsoumas DL; Ladis V; Spentzou A; Theodoridou MC
    Vaccine; 2006 Apr; 24(16):3050-3. PubMed ID: 16519975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fighting Haemophilus influenzae type b.
    Isaacs D
    Aust Fam Physician; 1993 Oct; 22(10):1886. PubMed ID: 8280020
    [No Abstract]   [Full Text] [Related]  

  • 36. Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.
    Fernández-Santana V; Cardoso F; Rodriguez A; Carmenate T; Peña L; Valdés Y; Hardy E; Mawas F; Heynngnezz L; Rodríguez MC; Figueroa I; Chang J; Toledo ME; Musacchio A; Hernández I; Izquierdo M; Cosme K; Roy R; Verez-Bencomo V
    Infect Immun; 2004 Dec; 72(12):7115-23. PubMed ID: 15557635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines.
    Gessner BD; Adegbola RA
    Vaccine; 2008 Jun; 26 Suppl 2():B3-8. PubMed ID: 18793604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of meningococcal serogroup C disease by NeisVac-C.
    Borrow R; Findlow J
    Expert Rev Vaccines; 2009 Mar; 8(3):265-79. PubMed ID: 19249967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.
    Denoël PA; Goldblatt D; de Vleeschauwer I; Jacquet JM; Pichichero ME; Poolman JT
    Clin Vaccine Immunol; 2007 Oct; 14(10):1362-9. PubMed ID: 17699836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avidity of Haemophilus influenzae type b antibody in UK infants.
    Berrington JE; Fenton AC; Arnaoutakis K; Zhang Q; Finn A
    Arch Dis Child; 2007 Sep; 92(9):827. PubMed ID: 17715451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.